Stock 2157 LEPU BIOPHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Lepu Biopharma Co., Ltd. Stock

Equities

2157

CNE100004SM4

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:39 2024-05-28 am EDT 		5-day change 1st Jan Change
4.52 HKD -3.00% Intraday chart for Lepu Biopharma Co., Ltd. -12.91% +7.36%
May. 24 Lepu Biopharma to Present Three Studies During US Cancer Meet; Shares Dip 7% MT
May. 24 Lepu Biopharma Co., Ltd. Announces Three Clinical Trial Results Presented At 2024 Asco Annual Meeting CI

Financials

Sales 2024 * 280M 38.62M 302M Sales 2025 * 270M 37.31M 291M Capitalization 7.4B 1.02B 7.97B
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * 28.7 x
Net Debt 2024 * 626M 86.36M 675M Net Debt 2025 * 820M 113M 884M EV / Sales 2025 * 30.4 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 429
Yield 2024 *
-
Yield 2025 *
-
Free-Float 31.85%
More Fundamentals * Assessed data

Chart Lepu Biopharma Co., Ltd.

Dynamic Chart

Latest news about Lepu Biopharma Co., Ltd.

Lepu Biopharma to Present Three Studies During US Cancer Meet; Shares Dip 7% MT
Lepu Biopharma Co., Ltd. Announces Three Clinical Trial Results Presented At 2024 Asco Annual Meeting CI
Lepu Biopharma Targets Up to HK$230 MIllion in Share Placement; Shares Fall 5% MT
Keymed Biosciences Advances Solid Tumors Drug With First Patient Study MT
Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lepu Biopharma's Pancreatic Cancer Drug Gets US FDA Fast-Track Designation MT
Lepu Biopharma Co., Ltd. Receives Fast Track Designation by the Food and Drug Administration of the United States for the Treatment of Pancreatic Cancer CI
Lepu Biopharma Shareholders to Vote Jan. 31 on Contract to Produce Drugs for Lepu Medical Technology MT
Lepu Biopharma Co., Ltd. Announces Completion of Patient Enrollment of Pivotal Phase IIb Clinical Trial for MRG003 for the Treatment of R/M NPC CI
Lepu Biopharma Completes Patient Enrollment for Phase 2B Trial for Nasopharyngeal Cancer Drug MT
Lepu Biopharma Renews Procurement Agreement With Lepu Medical Technology MT
Lepu Biopharma Gets US FDA's Orphan Drug Designation for Pancreatic Cancer Drug MT
Lepu Biopharma Co., Ltd. Announces Orphan-Drug Designation Granted by the FDA to MRG004A for the Treatment of Pancreatic Cancer CI
US FDA Grants Fast Track Designation to Lepu Biopharma's Anti-Cancer Drug MT
Lepu Biopharma to Provide Drug Production Services to Lepu Medical Technology MT
More news

News in other languages on Lepu Biopharma Co., Ltd.

AstraZeneca : accord de licence exclusif avec KYM Biosciences
More news

Quotes and Performance

1 day-3.00%
1 week-11.20%
Current month-17.97%
1 month-22.07%
3 months+13.57%
6 months+19.89%
Current year+7.36%
More quotes

Highs and lows

1 week
4.23
Extreme 4.23
5.18
1 month
4.23
Extreme 4.23
6.50
Current year
2.63
Extreme 2.63
6.50
1 year
2.63
Extreme 2.63
6.99
3 years
2.63
Extreme 2.63
31.80
5 years
2.63
Extreme 2.63
31.80
10 years
2.63
Extreme 2.63
31.80
More quotes

Managers and Directors - Lepu Biopharma Co., Ltd.

Managers TitleAgeSince
Ziye Sui CEO
 Chief Executive Officer - 20-04-21
Yun Yi Li DFI
 Director of Finance/CFO 44 20-12-09
Min MIn Qin CTO
 Chief Tech/Sci/R&D Officer 66 20-12-09
Members of the board TitleAgeSince
Feng Mao Hua BRD
 Director/Board Member 56 21-11-30
Zhong Jie Pu FOU
 Founder 61 18-01-18
Yang Xu BRD
 Director/Board Member 57 20-12-09
More insiders

ETFs positioned on Lepu Biopharma Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
1.63% 4 M€ -27.92%
More ETFs positioned on Lepu Biopharma Co., Ltd.

Quotes

Date Price Change Volume
24-05-28 4.52 -3.00% 12 401 000
24-05-27 4.66 +4.02% 15,192,000
24-05-24 4.48 -8.94% 13,820,000
24-05-23 4.92 -2.19% 2,922,000
24-05-22 5.03 -1.18% 10,917,270

Delayed Quote Hong Kong S.E., May 28, 2024 at 04:08 am EDT

More quotes

Company Profile

LePU Biopharma Co Ltd is a China-based biopharmaceutical company focused on tumor treatment. The Company mainly develops product lines of tumor candidate drugs, including antibody drug conjugate (ADC), oncolytic virus drug products and immunotherapy at clinical and pre-clinical stages. The Company’s major pipeline assets consist of MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates. The Company's products are sold at home and abroad.
Sector
Biotechnology & Medical Research
Calendar
2024-08-22 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Lepu Biopharma Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.324 CNY
Average target price
4.613 CNY
Spread / Average Target
+6.69%
Consensus

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LEPU BIOPHARMA CO., LTD. Stock Lepu Biopharma Co., Ltd.
+7.36% 1.02B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+12.30% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.15% 106B
BIONTECH SE Stock BioNTech SE
-8.14% 23.4B
ARGENX SE Stock argenx SE
-1.72% 22.1B
GENMAB A/S Stock Genmab A/S
-9.19% 18.34B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.70% 16.59B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.33% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.80% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.03% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2157 Stock